TO THE EDITOR: We have read the article by Su et al. with great interest (1). In our opinion, there is room for argument in the method and result of their study to reach their conclusion.
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Magnification or Nonmagnification:
That Is the Question TO THE EDITOR: We have read the article by Su et al. with great interest (1) . In our opinion, there is room for argument in the method and result of their study to reach their conclusion.
First, they have used a nonmagnifying colonoscope to identify the pit pattern of each polyp for histology prediction. Using a magnifying colonoscope for screening colonoscopy, lesions are often initially diagnosed on conventional view, and then are evaluated by chromoendoscopy with magnification followed by chromoendoscopy. Thus, we have conducted a prospective study to clarify if dye spraying and magnification used in each step contribute to further endoscopic distinction in comparison to conventional endoscopic view (2) . The overall diagnostic accuracy of chromoendoscopy with magnification was 95.6%, which was 10% and 5% significantly better than those of conventional view and chromoendoscopy without magnification, respectively. Su et al. also have previously reported the feasibility of chromoendoscopy with magnification for distinction of colonic polyps (3) . In the present study, they provided a similar result of interpreting the pit patterns with a nonmagnifying colonoscope. However, we can hardly identify the pit patterns presented in figures 5 and 8, which are obviously different from those presented in figures 1 and 2. We believed that the pictures of pit patterns shown in figures 1 and 2 were taken by a magnifying colonoscope but not a nonmagnifying one. Moreover, they also provided an extremely high interobserver agreement for interpreting pit patterns, which demonstrated that the kappa value was 0.960 for chromoendoscopy without magnification. Although, interobserver and intraobserver consistency in the endoscopic assessment of colonic pit patterns have been reported to be good for experienced endoscopists, the mean kappa for interobserver agreement was 0.776 (range 0.729-0.836), which was not as high as they described (4) . Additionally, despite the fact that the narrow band imaging (NBI) system is newly developed equipment that was not yet worldwide commercially available at the time of their study, even without magnification they also presented an excellent kappa value of NBI of 1.0. To the best of our knowledge, there are no such excellent data concerning pit pattern analysis with a nonmagnifying colonoscope as they have described in the present study. Actually, if nonmagnification could provide the same result as magnification, it would be much more convenient. However, in our opinion, they should provide clear images to show the reliability and reproducibility of their study.
In 1999, we developed a prototype NBI system with the assistance of Olympus Optical Co., Ltd., and we have reported that the observation of surface structure (pit pattern) using the NBI with magnification is useful for differentiating neoplasia from nonneoplasia (5) . Furthermore, we recently described that the presence of "meshed brown capillary vessels" on magnifying endoscopy with NBI is also useful for differential diagnosis without dye solution (6, 7) . Histologically, we also have evaluated microvascular proliferation with CD-31 immunohistochemical staining, and as a result, the diameter of meshed capillary (MC) vessels in normal colonic mucosa and hyperplastic polyps are reported to range from 8 to 12 µm, and are invisible or faintly visible under NBI with magnification. On the other hand, MC vessels in adenomatous or cancerous lesions range from 13 to 20 µm in diameter, and can be clearly visible under NBI with magnification. (2) , the latter of which is the primary metabolizing enzyme of selective serotonin reuptake inhibitors (SSRIs) and several other drugs (3). However, clinically relevant drug interactions with tegaserod were rarely reported to date. We have previously observed a panic attack after starting treatment with a regular dose of fluoxetine in a female patient with irritable bowel sydrome who was on tegaserod therapy (4) . The panic attack resolved right after discontinuation of tegaserod. SSRIs may cause a variety of adverse effects including panic attack, which are mostly associated with increased plasma drug levels (5) . Therefore, the condition in our patient was theoretically linked to an increase in plasma fluoxetine levels secondary to its decreased metabolism due to the effects of tegaserod on the enzymes responsible for the metabolism of fluoxetine. Nevertheless, the plasma fluoxetine level was not determined at the time of diagnosis, which limited the explanation of the true mechanism of the condition.
Kuang
I would like to ask Dr. Müller-Lissner and his coworkers whether they can present, in their large study population, some data about drug interactions possibly related to tegaserod, not only with SSRIs but also with the other agents. They note that 20% of the participants had nervous system comorbidity at baseline, which might be used to form a subgroup of people using SSRIs or other psychiatric drugs. If
Response to Dr. Tasci
TO THE EDITOR: In a letter to the editor, Dr. I. Tasci raises the question regarding potential drug-drug interactions of tegaserod, which might be related to its inhibitory effect on cytochrome P450 (CYP) isoenzymes CYP1A2 and CYP2D6.
In vitro studies with human liver microsomes have shown an inhibition of both CYP1A2 and CYP2D6 with inhibition constant (Ki) values of about 1 µmol/L, which is more than 100-fold above average Cmax following oral administration of the recommended daily dose of 6 mg twice daily. Subsequent in vivo studies were conducted using the prototype substrate theophylline (CYP1A2) and dextromethorphan (CYP2D6), which did not show any pharmacokinetic interaction, and the authors concluded that tegaserod has a low propensity to alter the PK of drugs that are metabolized by CYP1A2 and CYP2D6 (1) . It has also to be noted that 5-10% of Caucasians are considered poor metabolizers as they lack the 2D6 isoenzyme and therefore are subject to more side effects of fluoxetine (2) .
In a meta-analysis of phase III studies (overall N = 2,916) in irritable bowel syndrome, the safety profile of tegaserod in patients with/without concomitant antidepressants was investigated, of which 8.6% were on concomitant selective serotonin reuptake inhibitors (SSRIs). The safety profile was similar in patients with/without SSRIs (3). Panic attacks were very rarely observed in relation to tegaserod intake in clinical trials (<0.02%).
Thus, available data with tegaserod do not suggest that Dr. Tasci's observation of a patient with a panic attack on the combination therapy of tegaserod and SSRIs is related to a PK interaction. 
Stefan
Congenital Chloride Diarrhea: A Missed Diagnosis in an Adult Patient
TO THE EDITOR: Congenital chloride diarrhea (CCD) was first described by Gamble and Darrow in 1945 (1, 2) . It is a rare cause of childhood chronic diarrhea inherited as an autosomal recessive trait (3) . The basic defect is in the Cl-/HCO 3 -exchange mechanism of the distal ileum and colon, causing impaired active chloride absorption and bicarbonate secretion (4). Patients with CCD usually present within the first few months of life with profuse watery diarrhea, leading to paradoxical metabolic alkalosis, hypokalemia, hypochloremia, and growth retardation. Intrauterine diarrhea can cause polyhydramnios, dilated bowel loops, and premature birth. The prognosis of CCD is generally good. Most patients can achieve normal growth and development with adequate electrolyte replacement. We report a case of CCD in an adult patient whose diagnosis was initially missed. A 22-yr-old Chinese lady was seen in our outpatient clinic in December 2000 for chronic diarrhea since childhood. She used to pass watery stool three to four times per day. She accustomed to her symptom well and there was no other systemic symptom. Investigations including stool examination for common bacterial and parasitic pathogens were negative and colonoscopy was normal. At that moment, she had mild hypokalemia (K+ 3.3 mmol/L), but stool for electrolytes was not checked. She was initially diagnosed to have irritable bowel syndrome and reassured. She was lost to our follow-up since then. In January 2004, she attended the emergency department because of profuse watery diarrhea and generalized weakness for 3 days. She also had rhinorrhea and dry cough 2 wk before this presentation. Blood test showed that she had severe hypokalemia (K+ <1.5 mmol/L), hypochloremia (Cl-97 mmol/L), mild hyponatremia (Na+ 134 mmol/L), renal impairment (Cr 180 umol/L), and metabolic alkalosis (pH 7.67, HCO 3 -62 mmol/L). Thyroid function was normal. She denied any diuretics, laxatives, or weight-reducing agent consumption. She was admitted to our high dependency unit for aggressive fluid and electrolyte replacement and close observation. A careful history taking revealed that her two younger sisters suffered from CCD, which was diagnosed and followed up by pediatrician in another hospital. In fact, she belonged to one previously reported Chinese CCD family (5) . Unlike her sisters who presented with profuse watery diarrhea, severe electrolyte disturbance, and failure to thrive in their infancy, our patient's symptoms were much milder and not regarded as significant by her parents. Although CCD was once considered possible during family screening at that time, no regular follow-up was considered necessary in view of her mild symptoms and satisfactory weight gain. With this important information, subsequent investigations after electrolyte replacement and stabilization of her clinical condition showed stool for Na+ 98 mmol/L, K+ 33.8 mmol/L, Cl-was high at 146 mmol/L (stool Cl->Na+ plus K+), osmotic gap was 31.4 mOsm/kg (suggestive of secretory diarrhea). The diagnosis of CCD, which is the only diarrheal disorder associated with hypokalemic, hypochloremic alkalosis, was confirmed. She was discharged with long-term oral potassium chloride supplement with regular monitoring of her serum electrolytes in our outpatient clinic. We believe that her diarrhea existed since birth and she was well accustomed to it all along. Her current alarming presentation was likely due to aggravation of her diarrhea by recent upper respiratory tract infection and reduction in fluid and salt intake. Previous case report showed that intercurrent illness could exacerbate the diarrhea in patients with CCD (6).
This case illustrates the importance of careful history taking, including family history in the assessment of chronic diarrhea. CCD should be considered even in an adult patient, whose symptom in childhood may be mild. Early recognition and adequate electrolyte replacement can avert lifethreatening complications such as profound hypokalemia like our case and long-term complications such as renal impairment. (1) . Until the advent of CE, patients with OGB could have numerous investigations without necessarily finding a cause. CE now has an established role in patients who present with gastrointestinal bleeding but have a negative gastroscopy and colonoscopy (2) . However, the clinical factors that may improve the diagnostic potential of CE are unclear. Also, the majority of CE studies in OGB have failed to show a significant difference in diagnostic yield in patients with overt bleeding compared with occult bleeding (1, 3) .
Capsule Endoscopy and
We would like to share our experience of CE in patients with OGB (currently the largest reported cohort in the United Kingdom). Our aim was to identify factors that would predict a greater yield for CE. We studied 159 patients with OGB referred for CE over a 52-month period. Case notes were reviewed for type of OGB (occult/overt), age, sex, comorbidity, use of anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), and transfusion dependence. An average followup of 17 months was recorded.
Our U.K. data concur with Carey et al. (1) . Our total diagnostic yield was 53% and this was also notably higher in overt bleeders: 66% when compared with the occult group 46% (P < 0.025) (4). The commonest finding in both groups was angiodysplasia (AD, N = 35). Other diagnoses obtained included gastric antral vascular ectasia (GAVE) (6), GAVE and AD (6), tumor (9), polyps (2), Crohn's disease (3), NSAID ulceration (3), peptic ulcer disease (3), varices (2), small bowel ulcers (4), Dieulafoy (1), and miscellaneous (11).
Carey described advanced age as the only predictive factor in overt OGB. However, in our data set (using multivariate analysis), both transfusion dependence (P = 0.005) and co-morbidity (P < 0.0001) were significant predictive factors. The management was altered in 42% and 23% in the overt bleeders and occult bleeders, respectively (P < 0.025). This was in the form of endoscopic treatment of angioectasia: heater probe (16), variceal glueing (1), polypectomy (1), surgery (12), drug therapy (11: Helicobacter eradication/proton pump inhibitors [2] , thalidomide [3] , beta blockers [1] , azathioprine [1] /withdrawal of nonsteroidal antiinflammatory drugs [4] ), and initiation of a gluten-free diet (1).
In conclusion, transfusion dependence and comorbidity may also be significant predictors of a positive diagnostic yield. Further CE studies are required to validate these criteria, ensuring efficient use of the CE service. 
Royal Hallamshire Hospital, Sheffield S10 2JF, United Kingdom
Isotretinoin and Inflammatory Bowel Disease
TO THE EDITOR: We read with great interest the recent review published in your Journal by Reddy et al., which suggests a possible association between isotretinoin use and inflammatory bowel disease (IBD) (1). Although IBD is described as a possible adverse drug reaction in the product information, little attention has been given in the literature to this association.
In fact, we could not ignore the fact that the most common occurrence of isotretinoin prescription is in young adulthood, which also corresponds to the peak age for IBD onset. Knowing that abnormalities may not appear until months to years after its discontinuation, the association with prior isotretinoin use can easily go unnoticed (2) . So, besides a thorough history of IBD risk factors before isotretinoin prescription, gastroenterologists must be aware of this fact and ask for newly diagnosed patients with IBD about previous isotretinoin use.
It is conceivable that isotretinoin can act as a trigger for IBD in already predisposed individuals, or unmask symptoms in patients with preexisting subclinical disease (1, 2). While no well-documented relationship between acne and IBD exists, we might remember that other dermatologic lesions commonly included in the acne differential diagnosis may be associated with IBD, being described as extraintestinal manifestations, such as hidradenitis suppurativa (or acne inversa) (3). Thus, we might consider these dermatologic lesions as the first manifestation of IBD. In these circumstances, isotretinoin could be considered as neither acting as a trigger nor unmasking subclinical disease.
This discussion is supported by our own personal experience, in a case concerning a 19-yr-old female who had been on isotretinoin for genitofemoral acne inversa 20 mg/day for a year. There were no other gastrointestinal disorders on her previous medical and family history. One month before the end of treatment, she developed persistent aqueous diarrhea and progressive weight loss. Five months later, colonoscopy revealed an aftoid ileocolitis and pathological examination was compatible with Crohn's disease. There was a significant clinical improvement after starting oral mesalazine 3 g/day.
The relationship between isotretinoin and the emergence of Crohn's disease in this particular case, with no other risk factors for IBD, is clear. However, could we assume that acne inversa was not the first manifestation or a predisposing sign for Crohn's disease?
Endoscopic Management Is an Accepted First-Line Therapy for Biliary Complications After Adult Living Donor Liver Transplantation
TO THE EDITOR: We read the article by Tsujino et al. with interest (1). They evaluated the efficacy and safety of the endoscopic treatment for biliary complications after living donor liver transplantation (LDLT) with duct-to-duct anastomosis and concluded that the endoscopic approach can be a first-line therapy.
We also reported the efficacy for the endoscopic treatment of biliary complications after right-lobe LDLT (RL-LDLT) with duct-to-duct anastomosis (2, 3) . In our study, 273 patients underwent RL-LDLT, and the overall incidence of biliary complications was 34.1% (93 patients). Eighty patients developed biliary strictures (75 anastomotic and 5 nonanastmotic), and we successfully treated anastomotic strictures in 53 patients (70.7%) with endoscopic stenting. This endoscopic rescue rate is comparable to that of their report. A common issue raised by their study and ours concerns the difficulty in treating biliary strictures endoscopically. Our study revealed that endoscopic therapy is extremely difficult in nonanastomotic stricture and anastomotic stricture with crane-neck deformity (4). Only one of five (20%) patients with nonanastomotic stricture could be treated endoscopically. On the other hand, five out of 75 anastomotic strictures showed crane-neck deformity, which had two bended portions of common bile ducts. Again, only one of five (20%) cases with crane-neck deformity was successfully treated. Though the reasons for the development of crane-neck deformity remain unclear, this problem should be addressed in order to attain a higher success rate of endoscopic treatment.
One point to be noted is that there is a difference between our strategy and that of Tsujino et al. for the management of biliary strictures (1, 3) . They treated biliary strictures with balloon dilatation of strictures followed by temporary nasobiliary catheter (NBC) placement in eight of 12 patients, and biliary stents were used in the remaining four patients (insidestent). In contrast, we inserted inside-stents after balloon dilatation of biliary stricture as the first choice of treatment. In their discussion, the authors described that three of four patients with an inside-stent had an unfavorable outcome. This result is different from ours. Indeed, 55 of 75 patients with anastomotic stricture were treated with the inside-stents. As a result, endoscopic treatment was successfully achieved in 51 patients, except four cases who developed acute cholangitis within a week after stenting. Though the inside-stents were retrieved after an average of 269 days in 28 patients, 25 of 28 patients have been well without necessitating additional treatment for an average of 611 days. Twenty-one of the remaining 23 patients have been well with stenting for an average of 467 days. These results indicate that endoscopic placement of inside-stents, together with the combination of balloon dilatation and temporary NBC placement, is safe and useful as a first-line strategy for the treatment of biliary strictures. (the Kyoto group) regarding our recent article on endoscopic management of biliary complications after living donor liver transplantation (LDLT). Our initial success rate of endoscopic management of biliary strictures after LDLT (71%, 12 of 17 patients) seems to be comparable to that by the Kyoto group (68%, 54 of 80 patients) (1) . As stated in their correspondence, however, there is a considerable difference in the strategy for endoscopic management of biliary strictures between the two institutions. The Kyoto group inserted biliary stents across biliary strictures as the first-line therapy. On the other hand, our principle approach for biliary strictures was repetitive balloon (4-8 mm in diameter) dilation followed by nasobiliary catheter (NBC). Biliary stents were placed in the same manner by the Kyoto group ("inside stent") (1) when improvements of strictures were insufficient by balloon dilation and NBC placement. We have adopted this approach mainly for the following two reasons. (a) Our patients had more peripheral and complex biliary anastomoses as compared with those in their series (2, 3) . In the recipient operations, the hilar plate was dissected sharply at or distal to the second-order branch of the bile ducts, which were selected at the anastomotic sites with the graft bile ducts (2) . Therefore, we considered that it was difficult to place biliary stents adequately beyond the stricture. (b) Stent-related complications, especially acute cholangitis due to stent obstruction or migration, will occur as long as stents are in situ in the biliary system. Biliary strictures have been regarded to recur after they are solely dilated by balloon (4) . To prevent the recurrence, we placed an NBC through the stricture during the period of repetitive balloon dilation. In this protocol, five of nine patients (56%) without stent were free of recurrence during a median follow-up period of 10.1 months, and four patients with recurrent stricture were managed by repeated balloon dilation and an NBC insertion.
When repetitive balloon dilation and an NBC insertion fail to treat biliary strictures, biliary stent should be the preferred strategy prior to performing percutaneous or surgical intervention. This may account for their less favorable prognosis than those of the Kyoto group, although the number of our patients undergoing "inside stent" is too small (N = 4) to evaluate the efficacy of biliary stent.
Nonanastomotic strictures have been more difficult to manage endoscopically than anastomotic strictures. In our study, three of five patients with nonanastomotic strictures eventually underwent percutaneous or surgical treatment, being consistent with that of the Kyoto group (1). We cannot comment on endoscopic management of anastomotic stricture with "crane-neck" deformity (5) because we do not have the experience. The biliary system in LDLT may be more tortuous and more sharply angulated due to compensatory hypertrophy of donor liver as compared with that in diseased donor liver transplantation. The distorted bile duct makes an endoscopic approach difficult.
In a considerable number of patients with biliary strictures after LDLT in the Kyoto group, their results are impressive (1) . We absolutely concur with their statement that endoscopic management is the first-line therapy of biliary complications after LDLT. However, randomized controlled trials are imperative to compare the short-and long-term outcomes between biliary stent and balloon dilation following an NBC insertion for the treatment of biliary strictures after LDLT. There could be a subset of patients with biliary strictures who do not require stent insertion. A computerized tomography scan of the abdomen confirmed proximal ileum and jejunal thickening and separation of the ileal loops suggesting ileal edema. Antiviral therapy was discontinued, and therapy with prednisone and infliximab were initiated. After resolution of his CD flare, the prednisone was discontinued and because of the intent to restart his anti-HCV treatment, infliximab infusions 5 mg/kg were continued every 6 weeks. Upon rechallenge with antiviral therapy, he again normalized his liver enzymes and had an early viral response. He remained on concomitant infliximab, pegylated interferon, and ribavirin therapy without interruption or dose reduction for 48 weeks and achieved a sustained viral response ( Fig. 1) . He has remained negative for HCV nearly 4 years following completion of his antiviral therapy. Patients with autoimmune diseases and concomitant HCV infection are usually not treated for HCV due to the high likelihood of inducing a flare of the immune-mediated condition. To date, available information suggests that anti-TNFα therapy does not influence HCV viremia or hepatic inflammation (1, 2) . Anti-TNFα therapy in the setting of HCV maybe of particular interest in light of the growing body of evidence suggesting that the pathogenesis of hepatocyte destruction and fibrosis in HCV may be mediated by upregulation of inflammatory cytokines including TNFα (3). Furthermore, in a small trial, concomitant anti-TNFα therapy with etanercept resulted in better tolerance and improved virologic response to anti-HCV therapy (4) . The mechanisms of anti-TNFα therapy are incompletely understood but all anti-TNFα agents are not the same and infliximab but not etanercept has been found to result in apoptosis of lamina propria T cells (5) . Our case suggests that clearance of HCV with interferon plus ribavirin is not dependent on TNFα or the subset of cells that are cleared by infliximab. Our case demonstrates that treatment of hepatitis C is feasible in the presence of infliximab and that patients with CD and perhaps other immune-mediated diseases can be treated for HCV. Despite multiple negative predictors (high viral load, genotype 1, and cirrhosis), our patient achieved early and sustained viral response with concomitant use of antiviral therapy with infliximab. The safety of TNF blockade in the setting of chronic HCV infection as well as the ability to achieve a sustained viral response in concomitant use of infliximab with existing antiviral therapies for HCV requires further validation with larger case-series and/or clinical trials. Treatment of HCV patients with autoimmune disease must continue to be done carefully to avoid inducing a flare of the autoimmune disease. (1) describe the first report of tongue hyperpigmentation during peginterferon and ribavirin combination therapy in five nonwhite patients with hepatitis C virus (HCV) infection. The only risk factor for developing this complication appeared to be dark skin (1, 2), with no cases of lingual hyperpigmentation reported among 149 Caucasians receiving such therapy (1). We report the first case of tongue hyperpigmentation associated with peginterferon alfa-2b plus ribavirin administration in a Caucasian patient coinfected with HIV and HCV. A 53-yr-old white woman with history of HIV and HCV coinfection presented with a 7-wk history of burning sen- Figure 1 . Oral cavity of a 53-year-old Caucasian woman coinfected with HIV and hepatitis C virus, with angular cheilitis, tongue hyperpigmentation, and small erythematous papules of hard palate noted at 6 weeks of peginterferon alfa-2b plus ribavirin therapy. sation on her tongue. She has been treated with ritonavirboosted lopinavir, lamivudine, and tenofovir. Recently, she was started on therapy against HCV with peginterferon alfa2b plus ribavirin complicated with ribavirin-induced anemia. The patient began having tongue discomfort 1 wk after initiating HCV therapy. The pigmentary change was noted at 6 wk of therapy. Physical examination was significant for angular cheilitis, small erythematous papules of hard palate (Fig. 1) , and hyperpigmented patches on the lateral aspects of her tongue (Fig. 2) . Laboratory evaluation included a complete blood cell count, blood urea, creatinine, glucose, electrolytes, liver function tests, iron studies, serum folate, vitamin B 12 , cortisol, and TSH, which was only significant for anemia (hemoglobin 9.5 g/dL) and mild thrombocytopenia (platelets 149 × 10 9 cells/L). Oral hyperpigmentation has been reported in patients with Addison's disease, nutritional deficiencies, heavy metal exposure, amalgam tattoo, malignant melanoma, neurofibromatosis, Albright syndrome, and Peutz-Jegher's syndrome (3) . Medications can also cause tongue hyperpigmentation, including chloroquine, minocycline, clofazimine, ketoconazole, arsenic, bismuth, busulfan, bleomycin, doxorubicin, cyclophosphamide, melphalan, methyldopa, oral contraceptives, and tricyclic antidepressants (3). In HIV-infected patients, tongue hyperpigmentation has been observed in patients with Kaposi's sarcoma or those who have received zidovudine, clindamycin, spiramycin, and pyrimethamine (4, 5) . Our patient was not receiving any drug associated with tongue hyperpigmentation.
Manal
The temporal relation of the initiation of HCV therapy and the patient's tongue hyperpigmentation along with the lack of an alternative explanation for the observed pigmentary change make us speculate that peginterferon-alfa-2b and ribavirin therapy induced this abnormality. The mechanism of interferon-induced tongue hyperpigmentation is unknown, but it has been hypothesized that interferons can upregulate Figure 2 . Hyperpigmented patches on the lateral aspects of the tongue.
